title: Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.
authors.forename: Christian
authors.initials: C
authors.lastname: Rose
authors.forename: Martine
authors.initials: M
authors.lastname: Fournier
authors.forename: Olivier
authors.initials: O
authors.lastname: Nibourel
authors.forename: Charles
authors.initials: C
authors.lastname: Herbaux
authors.forename: Agnes
authors.initials: A
authors.lastname: Charpentier
authors.forename: Aline
authors.initials: A
authors.lastname: Renneville
authors.forename: Serge
authors.initials: S
authors.lastname: Pissard
authors.forename: Catherine
authors.initials: C
authors.lastname: Badens
authors.forename: Claude
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D019175:DNA Methylation / Q000187:drug effects*; D019143:Evolution, Molecular; D017809:Fatal Outcome; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D013577:Syndrome; D017085:alpha-Thalassemia / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine